NA-Fe, Zn and Mg chelate as well as preparation method and application thereof
Through the use of NA-Fe, Zn, Mg chelates, the problems of instability and adverse reactions of traditional iron supplements during storage, digestion and absorption are solved, and efficient iron absorption and stable hemoglobin synthesis are achieved, which is suitable for all Patients with iron deficiency anemia are especially suitable for special groups such as pregnant women and children.
Patent Information
- Application Number
- CN202310564421.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-18
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing traditional oral iron supplements are unstable during storage and digestion and absorption, which can easily cause adverse gastrointestinal reactions, and are not suitable for certain patients with special iron deficiency anemia, and have poor bioavailability.
Using NA-Fe, Zn, Mg chelates, chelates formed by tobaccoamine (NA), ferrous (Fe2+), zinc (Zn2+) and magnesium (Mg2+) are improved to improve iron utilization and absorption and promote hemoglobin synthesis , and it is stably absorbed in the gastrointestinal tract in molecular form to reduce adverse reactions.
It improves the bioavailability of iron, reduces gastrointestinal adverse reactions, is highly stable, is suitable for patients with various iron deficiency anemia, especially for special groups such as pregnant women and children, and is easy to store and industrially produce.
Smart Images

Figure CN118987243A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of food nutrition and medicine, relates to an iron supplement preparation, and in particular to a NA-Fe, Zn, Mg chelate and a preparation method and application thereof. Background Art
[0002] Anemia refers to the number of red blood cells and hemoglobin content in a certain volume of blood being lower than the normal range. Since the measurement of red blood cell volume is complicated, hemoglobin (Hb) concentration is often used instead in clinical practice. The diagnostic criteria formulated by WHO in 1972 believe that anemia is diagnosed when Hb is lower than the following levels in sea level areas: 110g / L for children aged 6 months to <6 years, 120g / L for children aged 6 to 14 years, 130g / L for adult males, 120g / L for adult females, and 110g / L for pregnant women. There are many causes of anemia, such as insufficient hematopoietic raw materials, iron deficiency, or iron utilization disorders (mainly manifested in affecting heme synthesis, resulting in smaller red blood cell morphology).
[0003] Iron is a metal element that the human body needs in large quantities. It is an important component of hemoglobin in red blood cells. The average adult body contains 3-4 grams of iron. Normal iron nutrition plays an important role in maintaining human health. Nearly one-tenth of the population in my country suffers from anemia, and iron deficiency is the most common cause of anemia.
[0004] Most of the traditional oral iron supplements on the market (such as ferrous sulfate and ferrous chloride) are single iron supplements that only supplement the body's insufficient iron content. They are not only prone to cause erosive mucosal damage in the upper digestive tract, but also lead to adverse reactions such as nausea, vomiting, upper abdominal discomfort, diarrhea, and constipation. In addition, it is not suitable for some special groups of people with iron deficiency anemia, such as malaria, ileitis, and chronic ulcerative colitis.
[0005] On the other hand, although traditional oral iron supplements are cheap and high in iron, they are unstable in nature and can easily deteriorate during storage or be affected by other ingredients in food during digestion and absorption, resulting in poor oral bioavailability of the iron. Summary of the invention
[0006] The technical problem to be solved by the present invention is to provide a NA-Fe, Zn, Mg chelate and a preparation method and application thereof in order to overcome at least one defect in the prior art.
[0007] The present invention solves the above technical problems through the following technical solutions:
[0008] The first aspect of the present invention provides a NA-Fe, Zn, Mg chelate, which is a nicotianamine NA (NA is the abbreviation of nicotianamine) combined with Fe 2+ 、Zn2+ and Mg 2+ of chelate.
[0009] Preferably, the chelate comprises NA-Fe, NA-Zn and NA-Mg;
[0010] in:
[0011] The NA-Fe is NA combined with Fe 2+ Chelates,
[0012] The NA-Zn is NA combined with Zn 2+ Chelates,
[0013] The NA-Mg is NA combined with Mg 2+ of chelate.
[0014] Preferably, in the chelate, the molar ratio of Fe element, Zn element and Mg element is 1:0.3-0.9:38.5-64.2; preferably, the molar ratio of Fe element, Zn element and Mg element is 1:0.3:38.5.
[0015] Zinc is a metal component of many important enzymes in the body and is involved in the synthesis of hemoglobin. The zinc in the NA-Fe, Zn, Mg chelate of the present invention can improve the utilization and absorption of iron, promote hemoglobin synthesis, and has the function of maintaining the stability of red blood cell membranes and protecting red blood cells from certain hemolysins.
[0016] Magnesium also plays an active role in hemoglobin synthesis and erythrocyte membrane stability. Magnesium deficiency can cause erythrocyte enzyme defects, hemoglobin synthesis defects, erythrocyte membrane structural defects, etc. The magnesium in the NA-Fe, Zn, Mg chelate of the present invention participates in many biochemical reactions and metabolic processes. In particular, magnesium can affect the intracellular and extracellular transfer of potassium, sodium, and calcium ions, especially playing an important role in energy metabolism. Energy plays a very important role in the normal distribution of erythrocyte membrane phospholipids. When energy is reduced, the activity of aminophospholipid translocase decreases, and the serine phospholipids in the outer layer cannot be normally flipped to the inner layer of erythrocyte membrane lipids to activate prothrombin, resulting in platelet aggregation, causing erythrocytes to be finally engulfed. Therefore, magnesium plays a very important role in maintaining the stability of erythrocyte membrane structure.
[0017] In the present invention, the NA-Fe, Zn, Mg chelate obtained by combining NA-Fe chelate with NA-Zn and NA-Mg is a chelate of a small molecule organic acid NA (NA is the abbreviation of nicotianamine) combined with ferrous iron, zinc and magnesium. In a preferred embodiment, when the molar ratio of Fe element, Zn element and Mg element in the chelate is 1:0.3:38.5, the iron content is 0.44%, the zinc content is 0.15%, and the magnesium content is 7.21%. The chelate has high water solubility, can be completely absorbed in molecular form, has high oral bioavailability and promotes the production of red blood cells. The NA-Fe, Zn, Mg chelate does not contain free ferrous ions, zinc ions and magnesium ions, so there are few gastrointestinal adverse reactions. In addition, NA-Fe, NA-Zn, and NA-Mg are stable and easy to store at room temperature. Because they exist in the form of molecules in the body, the structure is similar to the ferritin core in intestinal cells. They are absorbed into the body through divalent metal ion transporters. This absorption into the blood through transporters will not cause local excessive concentrations leading to acute poisoning. NA-Fe, Zn, and Mg chelate mixtures can prevent and treat iron deficiency anemia, prevent iron deficiency anemia in special populations such as infants, children, adolescents, and women (especially pregnant women), and can also prevent and treat anemia caused by insufficient hematopoietic raw materials or utilization disorders.
[0018] Preferably:
[0019] In the NA-Fe, the molar ratio of NA to Fe is 10:1-1:1;
[0020] In the NA-Zn, the molar ratio of NA to Zn element is 10:1-1:1;
[0021] In the NA-Mg, the molar ratio of NA to Mg element is 10:1-1:1.
[0022] The second aspect of the present invention provides a method for preparing the NA-Fe, Zn, Mg chelate, comprising the following steps:
[0023] The ferrous compound reacts with NA in water to obtain NA-Fe;
[0024] reacting a zinc compound with NA in water to obtain NA-Zn;
[0025] reacting a magnesium compound with NA in water to obtain NA-Mg;
[0026] NA-Fe, NA-Zn and NA-Mg are mixed to obtain the NA-Fe, Zn, Mg chelate.
[0027] The preparation method of the NA-Fe, Zn, Mg chelate of the present invention has fewer reaction steps, mild reaction conditions, and the NA-Fe, Zn, Mg chelate combination reaction is easy to master. As long as the reaction is carried out according to the ingredients and operating conditions, a yield of more than 90% can be achieved. The process flow of producing the NA-Fe, Zn, Mg chelate is simple, the conditions are mild, the reproducibility is good, the process conditions are reliable, no refrigeration equipment is required, and the process is operable; and no waste gas is generated during the reaction, which reduces the explosion hazard that may be caused by excessive pressure in the reaction tank in industrial production, and does not involve toxic chemical reagents.
[0028] Preferably:
[0029] The ferrous compound includes but is not limited to ferrous chloride, ferrous sulfate, ferrous nitrate or ferrous lactate, etc.;
[0030] The zinc compound includes but is not limited to zinc sulfate, zinc chloride, zinc nitrate or zinc acetate;
[0031] The magnesium compound includes but is not limited to magnesium sulfate, magnesium chloride, magnesium nitrate or magnesium chromate;
[0032] In the step of mixing NA-Fe, NA-Zn and NA-Mg, the ratio of the NA-Fe, the NA-Zn and the NA-Mg satisfies that the molar ratio of the Fe element, the Zn element and the Mg element is 1:0.3-0.9:38.5-64.2.
[0033] Preferably:
[0034] In the step of reacting the ferrous compound with NA in water to obtain NA-Fe, the ferrous compound is added to the water, NA is added within a preset time range, the temperature is controlled at the reaction temperature, the reaction is carried out for a preset reaction time, a colorless solution is generated, the solution is purified, and dried to obtain the NA-Fe;
[0035] In the step of reacting the zinc compound with NA in water to obtain NA-Zn, the zinc compound is added to water, NA is added within a preset time range, the temperature is controlled at the reaction temperature, the reaction is carried out for a preset reaction time, a colorless solution is generated, the solution is purified, and dried to obtain the NA-Zn;
[0036] In the step of reacting the magnesium compound with NA in water to obtain NA-Mg, the magnesium compound is added to the water, NA is added within a preset time range, the temperature is controlled at the reaction temperature, the reaction is carried out for a preset reaction time, a colorless solution is generated, the solution is purified, and dried to obtain the NA-Mg;
[0037] Further preferably, the preset time range is 5-20 minutes, the molar ratio of the NA to the ferrous compound, the zinc compound or the magnesium compound is 10:1-1:1, the reaction temperature is 25-37°C, the preset reaction time is 15min-24h, the reaction is carried out under vortex oscillation, the purification is performed by preparative chromatography on the sample, and the drying is performed by N2 drying.
[0038] Preferably, the step of reacting the ferrous compound with NA in water to obtain NA-Fe is carried out in the presence of a reducing agent, the reducing agent includes ascorbic acid, sodium citrate, potassium tartrate or sodium phosphite, and the concentration of the reducing agent in the reaction system is 5-15 mmol / L. The main function of reducing agents such as ascorbic acid is to prevent ferrous ions from being oxidized to ferric ions by utilizing their reducing properties when preparing ferrous solution.
[0039] The third aspect of the present invention provides the use of the NA-Fe, Zn, Mg chelate in the preparation of a drug for treating and / or preventing ischemic anemia, and / or preventing and treating anemia caused by insufficient or impaired utilization of hematopoietic raw materials.
[0040] A fourth aspect of the present invention provides a pharmaceutical composition containing NA-Fe, Zn, Mg chelate, wherein the pharmaceutical composition is a powder, granules, tablets, pills, capsules or syrup containing the NA-Fe, Zn, Mg chelate.
[0041] Preferably, the pharmaceutical composition is a capsule containing NA-Fe, Zn, Mg chelate.
[0042] Further preferably, the daily dose of the pharmaceutical composition is no more than 62 mg / kg body weight as calculated as NA-Fe, Zn, Mg chelate. Further preferably, the daily dose is 12-62 mg / kg body weight; more preferably, the daily dose is 62 mg / kg body weight.
[0043] The positive and progressive effects of the present invention are:
[0044] 1. The present invention directly prepares a variety of metal elements into chelates, thereby improving the stability of ferrous salts at room temperature and preventing the ferrous salts from being hydrolyzed during storage.
[0045] 2. The present invention is absorbed in a complete form through intestinal transporters, which reduces the irritation of the free ferrous salt to the gastrointestinal tract, reduces adverse reactions and increases the use of patients with diseases such as peptic ulcers and ileitis.
[0046] 3. The preparation method of the present invention has a simple process, good separation and purification effect, is easy to realize industrial production, does not use organic solvents, does not produce toxic gases, and is beneficial to environmental protection. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 This is the magnesium ion chelation value (chelation value K) and pH curve.
[0048] Figure 2 This is the iron ion chelation value (chelation value K) and pH curve.
[0049] Figure 3 This is the zinc ion chelation value (chelation value K) and pH curve.
[0050] Figure 4 The following are the identification experimental results of the NA-Fe, Zn, Mg chelates obtained in the preparation example of the present invention. DETAILED DESCRIPTION
[0051] A NA-Fe, Zn, Mg chelate, which is nicotianamine NA (NA is the abbreviation of nicotianamine) combined with Fe 2+ 、Zn 2+ and Mg 2+ of chelate.
[0052] In some embodiments, the chelate comprises NA-Fe, NA-Zn, and NA-Mg;
[0053] in:
[0054] NA-Fe is NA combined with Fe 2+ Chelates,
[0055] NA-Zn is NA combined with Zn 2+ Chelates,
[0056] NA-Mg is NA combined with Mg 2+ of chelate.
[0057] In some embodiments, in the chelate, the molar ratio of Fe element, Zn element and Mg element is 1:0.3-0.9:38.5-64.2. For example, when the amount of Fe element is 1, the amount of Zn element can be 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, etc., and the amount of Mg element can be 38.5, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 64.2, etc.; preferably, the molar ratio of Fe element, Zn element and Mg element is 1:0.3:38.5.
[0058] In some embodiments:
[0059] In NA-Fe, the molar ratio of NA to Fe element is 10:1-1:1; for example, it can be 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, etc.
[0060] In NA-Zn, the molar ratio of NA to Zn element is 10:1-1:1; for example, it can be 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, etc.
[0061] In NA-Mg, the molar ratio of NA to Mg element is 10:1-1:1; for example, it can be 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, etc.
[0062] The preparation method of NA-Fe, Zn, Mg chelate comprises the following steps:
[0063] The ferrous compound reacts with NA in water to obtain NA-Fe;
[0064] reacting a zinc compound with NA in water to obtain NA-Zn;
[0065] reacting a magnesium compound with NA in water to obtain NA-Mg;
[0066] NA-Fe, NA-Zn and NA-Mg are mixed to obtain NA-Fe, Zn, Mg chelate.
[0067] In some embodiments:
[0068] Ferrous compounds include but are not limited to ferrous chloride, ferrous sulfate, ferrous nitrate or ferrous lactate;
[0069] Zinc compounds include but are not limited to zinc sulfate, zinc chloride, zinc nitrate or zinc acetate;
[0070] Magnesium compounds include but are not limited to magnesium sulfate, magnesium chloride, magnesium nitrate or magnesium chromate;
[0071] In the step of mixing NA-Fe, NA-Zn and NA-Mg, the ratio of NA-Fe, NA-Zn and NA-Mg satisfies: the molar ratio of Fe element, Zn element and Mg element is 1:0.3-0.9:38.5-64.2. For example, when the amount of Fe element is 1, the amount of Zn element can be 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, etc., and the amount of Mg element can be 38.5, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 64.2, etc.; preferably, the molar ratio of Fe element, Zn element and Mg element is 1:0.3:38.5.
[0072] In some embodiments:
[0073] The ferrous compound is reacted with NA in water to obtain the step of NA-Fe, wherein the ferrous compound is added to the water, NA is added within a preset time range, the temperature is controlled at a reaction temperature, the reaction is carried out for a preset reaction time, a colorless solution is generated, and the solution is purified and dried to obtain NA-Fe;
[0074] In the step of reacting the zinc compound with NA in water to obtain NA-Zn, the zinc compound is added to water, NA is added within a preset time range, the temperature is controlled at a reaction temperature, the reaction is carried out for a preset reaction time, a colorless solution is generated, and the solution is purified and dried to obtain NA-Zn;
[0075] In the step of reacting a magnesium compound with NA in water to obtain NA-Mg, a magnesium compound is added to water, NA is added within a preset time range, the temperature is controlled at a reaction temperature, the reaction is carried out for a preset reaction time, a colorless solution is generated, and the solution is purified and dried to obtain NA-Mg;
[0076] In some embodiments, the preset time range is 5-20 minutes, for example, it can be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc.; the molar ratio of NA to the ferrous compound, zinc compound or magnesium compound is 10:1-1:1, for example, it can be 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, etc.; the reaction temperature is 25-37°C, for example, it can be 25°C, 26°C, 27°C, 28°C, 29 ℃, 30℃, 31℃, 32℃, 33℃, 34℃, 35℃, 36℃, 37℃, etc.; the preset reaction time is 15min-24h, for example, it can be 30min, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 11h, 12h, 13h, 14h, 15h, 16h, 17h, 18h, 19h, 20h, 21h, 22h, 23h, 24h, etc.; the reaction is carried out under vortex oscillation, the purification is carried out by preparative chromatography on the sample, and the drying is carried out by N2 drying.
[0077] In some embodiments, the step of reacting a ferrous compound with NA in water to obtain NA-Fe is carried out in the presence of a reducing agent, the reducing agent including ascorbic acid, sodium citrate, potassium tartrate or sodium phosphite, and the concentration of the reducing agent in the reaction system is 5-15 mmol / L, for example, 5 mmol / L, 6 mmol / L, 7 mmol / L, 8 mmol / L, 9 mmol / L, 10 mmol / L, 11 mmol / L, 12 mmol / L, 13 mmol / L, 14 mmol / L, 15 mmol / L, etc. The main function of reducing agents such as ascorbic acid is to prevent ferrous ions from being oxidized to ferric ions by utilizing their reducing properties when preparing ferrous solution.
[0078] Application of NA-Fe, Zn, Mg chelate in the preparation of medicines for treating and / or preventing ischemic anemia, and / or preventing and treating anemia caused by insufficient or utilization disorders of hematopoietic raw materials.
[0079] A pharmaceutical composition containing NA-Fe, Zn, Mg chelate, wherein the pharmaceutical composition is powder, granules, tablets, pills, capsules or syrup containing NA-Fe, Zn, Mg chelate.
[0080] In some embodiments, the pharmaceutical composition is a capsule containing NA-Fe, Zn, Mg chelate.
[0081] In some embodiments, the pharmaceutical composition is calculated as NA-Fe, Zn, Mg chelate, and the daily dose is no more than 62 mg / kg body weight. The preferred daily dose is 12-62 mg / kg body weight; and the more preferred daily dose is 62 mg / kg body weight.
[0082] Figure 1 , Figure 2 and Figure 3 The pH curves of magnesium ion chelation value (chelation value K), iron ion chelation value (chelation value K) and zinc ion chelation value (chelation value K) and pH curves are shown respectively.
[0083] Figure 1 The results showed that the chelation effect of NA and Fe was better in the pH range of 5-9.
[0084] Figure 2 The results showed that the chelation effect of NA and Mg was better in pH=5 buffer.
[0085] Figure 3 The results showed that the chelation effect of NA and Zn was better in the pH range of 5-8.
[0086] In summary, the chelation ranges of NA, Fe and Zn are relatively close, and the chelation results are better in the pH range of about 5-8. Although NA and Mg have better chelation effects in pH = 5 buffer, about 80% of the metals exist in the form of chelates under neutral conditions of pH = 7. For the sake of green and environmental protection, a neutral environment was selected as the experimental system.
[0087] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the specific implementation methods of the present invention will be described below with reference to the accompanying drawings. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings and other implementation methods can be obtained based on these drawings without creative work.
[0088] Unless otherwise specified, the raw materials and equipment used in the present invention are commercially available.
[0089] Preparation Example
[0090] 1. Preparation of NA-Fe:
[0091] Add an appropriate amount of ascorbic acid and an appropriate amount of purified water or distilled water into a centrifuge tube and dissolve into an ascorbic acid solution with a concentration of 10mM (10mmol / L); add 9.94mg of ferrous chloride and 5mL of the above ascorbic acid solution into another centrifuge tube; within 5 minutes, add NA solution at a certain molar ratio, and the molar ratio of NA and ferrous chloride (containing 10mmol / L Vc) follows a 1:1 ratio. The reaction temperature is raised to 25 degrees Celsius and vortexed for 15 minutes; the reaction solution gradually fades from light green to form a colorless solution; take an appropriate amount of sample and purify the sample by preparative chromatography. The purified sample is dried with N2;
[0092] 2. Preparation of NA-Zn:
[0093] Add 10 grams of purified water or distilled water to a centrifuge tube, and then add 28.7 milligrams of zinc sulfate; after 5 minutes, add NA solution according to a certain molar ratio, the molar ratio of NA to zinc sulfate follows a 1:1 ratio, the reaction temperature is raised to 25 degrees Celsius, and vortexed for 15 minutes; a colorless solution is generated; take an appropriate amount of sample and purify the sample by preparative chromatography. The purified sample is dried with N2.
[0094] 3. Preparation of NA-Mg:
[0095] Add 10 grams of purified water or distilled water to a centrifuge tube, and control the reaction temperature at 25 degrees Celsius; then add 24.6 milligrams of magnesium sulfate; after 5 minutes, add NA solution at a certain molar ratio, and the molar ratio of NA to magnesium sulfate follows a 1:1 ratio. The reaction temperature is raised to 25 degrees Celsius, and vortexed for 15 minutes; the reaction solution gradually fades from blue to a colorless solution; take an appropriate amount of sample and purify the sample by preparative chromatography. The purified sample is dried with N2.
[0096] 4. Mix the above powders in a molar ratio of 1:0.3:38.5 and put them into capsules at a concentration of 75 mg.
[0097] Summary: The preparation method of NA-Fe, Zn, Mg chelate of the present invention has few reaction steps and mild reaction conditions. The NA-Fe, Zn, Mg chelate binding reaction is easy to master, and the yield can be achieved as long as the reaction is carried out according to the ingredients and operating conditions. The process flow for producing NA-Fe, Zn, Mg chelate is simple, but the conditions should be mild, the reproducibility is good, the process conditions are reliable, no refrigeration equipment is required, and it is operable; and no waste gas is generated during the reaction, which reduces the explosion hazard caused by excessive pressure in the reaction tank in industrial production, and does not involve toxic chemical reagents.
[0098] Experimental Example 1
[0099] Identification experiment of NA-Fe, Zn, Mg chelate obtained in the preparation example of the present invention
[0100] 1. Purpose of the experiment
[0101] The NA-Fe, NA-Zn and NA-Mg chelates obtained by the preparation method of the present invention are identified by hydrolysis.
[0102] 2. Materials and Methods
[0103] Weigh a certain amount of NA-Fe, NA-Zn, and NA-Mg chelates respectively, mix them in a molar ratio of 1:0.3:38.5, dissolve them with 1 mL of sterile water for injection, take 500 μL of the sample and put it into a test tube and dry it. Add 1 mL of nitric acid to the test tube and nitrolyze it. Add ultrapure water to the nitrolyzed sample to make it up to 10 ml and mix well. Take 300 μL of the diluted sample and detect it by inductively coupled plasma-mass spectrometry (ICP-MS). For results, see Figure 4 .
[0104] In this experiment, inductively coupled plasma mass spectrometry was used to identify and test NA-Fe, NA-Zn, and NA-Mg chelates. The experimental results confirmed the real existence of three metal elements, Fe, Zn, and Mg, in the solution.
[0105] Experimental Example 2
[0106] Experimental study on the content of NA-Fe, Zn, Mg chelates obtained in the preparation example of the present invention
[0107] 1. Experimental purpose: To determine the content of NA-Fe, Zn, Mg chelates obtained by the preparation method of the present invention by LC-MS / MS method.
[0108] 2. Materials and Methods
[0109] Weigh a certain amount of NA-Fe, NA-Zn, and NA-Mg chelates, mix them in a molar ratio of 1:0.3:38.5, and dissolve them with 1 mL of sterile water for injection. Take 500 μL of the sample and put it into a test tube and dry it. Add 1 mL of nitric acid to the test tube and nitrolyze it. Add ultrapure water to the nitrolyzed sample to make it 10 mL and mix it well. Dilute the sample 2 times with ultrapure water at a ratio of 1:1 (v / v), take 300 μL of the sample, and detect it by inductively coupled plasma-mass spectrometry (ICP-MS). The results are shown in Table 1.
[0110] Table 1 Determination of the content of NA-Fe, Zn, Mg chelates
[0111]
[0112]
[0113] In this experiment, inductively coupled plasma mass spectrometry was used to test the content of NA-Fe, NA-Zn, and NA-Mg chelates. The experimental results showed that the molar concentration ratio of the three metal ions Fe:Zn:Mg was 1:0.39:38.6, which basically met the theoretical molar ratio of the three chelate mixtures.
[0114] Experimental Example 3
[0115] Comparative experiment on the effect of NA-Fe, Zn, Mg chelate obtained in the preparation example of the present invention on anti-iron deficiency anemia
[0116] 1. Experimental purpose
[0117] The iron deficiency anemia animal model was established by feeding a low-iron diet and blood loss modeling to investigate the pharmacodynamic effects of the NA-Fe, Zn, Mg chelate prepared by the preparation method of the present invention.
[0118] 2. Materials and Methods
[0119] 2.1 Materials
[0120] 2.1.1 Drugs
[0121] The NA-Fe group prepared by the preparation method of the present invention; the NA-Fe, Zn group; the NA-Fe, Mg group and the NA-Fe, Zn, Mg chelate group obtained in the preparation example of the present invention, wherein the NA-Fe, Zn, Mg chelate components are divided into 3 groups, namely, a low-dose group, a medium-dose group and a high-dose group.
[0122] Ferrous sulfate, (Alfa Aesar, lot number: R07G093)
[0123] Each group was given a solution of different concentrations by intragastric administration with sterile water for injection every day. The model group and the normal control group were given sterile water for injection by intragastric administration.
[0124] 2.1.2. Animals
[0125] Kunming mice
[0126] 2.1.3 Feed:
[0127] 1) General animal feed.
[0128] 2) Low-iron feed: prepared according to the formula of low-iron feed (including 54% corn starch, 40% milk powder, 5% soybean oil, and 1% salt).
[0129] 2.1.4 Instruments:
[0130] The instrument is used for red blood cell counting (F-820 fully automatic blood cell counter, produced by Japan Best Co., Ltd.; Sysnex DB-1 sample cup (coated with hemolysis inhibitor)) or other methods can be used to count the number of red blood cells.
[0131] 2.1.5 Reagents
[0132] Sysnex Hemolysin, diluent, distilled water
[0133] 2.2 Experimental methods:
[0134] 2.2.1 Replication of iron deficiency anemia animal model:
[0135] Fifty healthy male animals were selected, 5 of which were used as normal controls. They were fed with normal feed and drank filtered water. Another 45 animals were kept in animal cages and fed with low-iron feed and filtered water. After 3 consecutive days of low-iron feed, 10 drops of blood were drawn from the tail vein of each animal except the normal control group. After bleeding, 15 drops of blood were drawn from the tail vein of each animal except the normal control group. 24 hours after the bleeding, blood was taken to measure hemoglobin (Hb) and red blood cells (RBC). Hb decreased from 12.93±1.49 (g / dl) to 8.4±7.61 (g / dl), and RBC decreased from 8.08±0.85 (10 12 / L) decreased to 6.06±0.61(10 12 / L) and was statistically significant compared with the normal group of mice. At the same time, the animals showed symptoms such as mental depression, fluffy fur, and inactivity, proving that the animal model of iron deficiency anemia has been established.
[0136] 2.2.2 Blood-tonifying effect on iron-deficiency anemia mice:
[0137] The above 45 animals with iron deficiency anemia were screened, and all those with Hb below 11g / dl were selected. The selected animals with iron deficiency anemia were randomly divided into 8 groups according to the data, namely ferrous sulfate group (dose 0.5mg / kg / day), model group (normal saline), NA-Fe chelate group, NA-Fe, Zn chelate group, NA-Fe, Mg chelate group and 3 NA-Fe, Zn, Mg chelate groups (high dose group 62mg / kg / day, medium dose group 25mg / kg / day, low dose group 12mg / kg / day). Except for the normal control group fed with general feed, the other groups continued to feed low iron feed. The animals in each group were given the above drugs by gavage, with a volume of 10ml / kg body weight, once a day, for 8 consecutive days. The model group and the normal control group were given the same volume of sterile water for injection every day. Blood was taken on the 8th day to measure Hb and RBC, and the results were statistically analyzed using t test.
[0138] 3. Experimental results
[0139] The experimental results are shown in Table 2:
[0140] Table 2 Effects of different groups on hemoglobin and red blood cells in animals with iron deficiency anemia
[0141]
[0142] Note: Compared with the normal group, p Hb <0.05,p RBC <0.01
[0143] Compared with the model group, p Hb <0.05,p RBC <0.01
[0144] Compared with the ferrous sulfate group, p Hb <0.05,p RBC <0.01
[0145] 4. Summary
[0146] The rat hemoglobin recovery experiment established by Pla and Prizl et al. was adopted as an official method in the United States in 1971. In this experiment, an animal model of iron deficiency anemia was successfully established using adult animals according to this method. The Hb of healthy animals decreased from 12.93±1.49 (g / dl) to 8.4±7.61 (g / dl), and the RBC decreased from 8.08±0.85 (1012 / L) to 6.06±0.61 (1012 / L), and there was a statistically significant difference compared with the normal group of animals. At the same time, the animals showed symptoms such as mental depression, fluffy fur, and inactivity, proving that the animal model of iron deficiency anemia has been established.
[0147] After continuous oral administration for 8 days, blood was taken to measure hemoglobin and red blood cells. The results showed that the NA-Fe, Zn, Mg chelate groups of the present invention and ferrous sulfate significantly improved iron deficiency anemia. The effect of the high-dose NA-Fe, Zn, Mg chelate group was better than the trend of administration of other groups, and there was a significant difference compared with the ferrous sulfate group.
[0148] Description of high, medium and low dosage groups of NA-Fe, Zn, Mg chelates:
[0149] According to the International Union of Nutritional Sciences' daily nutritional requirements for healthy people aged 18-55, Fe / Zn / Mg (10:12:315 mg, total molar ratio 0.18:0.18:13), Fe:Zn:Mg = 1:1:100 mol / mol / mol.
[0150] Iron: The appropriate iron intake (AI) for adult males is 12 mg / day, and for females is 20 mg / day. The upper tolerable intake level (UL) is 50 mg / day for both males and females.
[0151] Zinc: The recommended zinc intake (RNI) for adult men is 12.5 mg / day, and for women it is 7.5 mg / day, and the UL is 45 mg / day.
[0152] Magnesium: The recommended daily intake (AI) for magnesium for adults is 330 mg / day (magnesium is a major element and there is no maximum tolerable amount).
[0153] Reference values of trace elements for adults:
[0154] Serum iron: 24.3-26.9 μmol / L;
[0155] Serum zinc: 7.65-22.95 μmol / L;
[0156] Serum magnesium: 0.75-1.25mmol / L.
[0157] The daily dose is set according to the iron content, with the high-dose group equivalent to the maximum intake, the medium-dose group equivalent to the daily intake for women, and the low-dose group equivalent to the daily intake for men.
[0158] The following Tables 3 to 6 are reference tables for dosage settings:
[0159] Table 3 Statistics of daily requirement and tolerance of NA-metal ions (mg)
[0160]
[0161] Table 4 Statistics of daily requirement and tolerance of NA-metal ions (mg)
[0162]
[0163]
[0164] Table 5 NA-metal ion daily dosage setting (mg / kg / day)
[0165] name Low dose Medium dose High dose NA-Metal (Human Body) 1 2 5 NA-Metal (mouse) 12 25 62
[0166] Note: The dosage for mice is approximately 12.3 times that for humans
[0167] Table 6 Statistics of daily requirement and tolerance of NA-metal ions (mol)
[0168]
[0169] Note: The NA-Fe / NA-Zn / NA-Mg molar ratio is set (1:0.3:38.5) based on the low molar number.
[0170] Experimental Example 4
[0171] Stability test of NA-Fe, Zn, Mg chelate obtained in the preparation example of the present invention at room temperature
[0172] The NA-Fe, Zn, Mg chelate obtained in the preparation example of the present invention was dissolved in ultrapure water to prepare a 10 μmol / L working solution, and the working solution was placed at room temperature overnight for 19 hours. The peak area of the chromatographic peak of the NA-Fe, Zn, Mg chelate was determined by liquid chromatography-mass spectrometry to investigate the stability of the NA-Fe, Zn, Mg chelate at room temperature. The experimental results are shown in Table 7.
[0173] Table 7 Room temperature stability study
[0174]
[0175]
[0176] The experimental results show that the three chelates of NA-Fe, Zn and Mg are stable at room temperature for 19 hours.
[0177] It should be noted that the above embodiments can be freely combined as needed. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered as the protection scope of the present invention.
Claims
1. A NA-Fe, Zn, Mg chelate, characterized in that: It is NA combined with Fe 2+ 、Zn 2+ and Mg 2+ of chelate.
2. The NA-Fe, Zn, Mg chelate according to claim 1, characterized in that: The chelate comprises NA-Fe, NA-Zn and NA-Mg; in: The NA-Fe is NA combined with Fe 2+ Chelates, The NA-Zn is NA combined with Zn 2+ Chelates, The NA-Mg is NA combined with Mg 2+ of chelate.
3. The NA-Fe, Zn, Mg chelate according to claim 1 or 2, characterized in that: In the chelate, the molar ratio of Fe element, Zn element and Mg element is 1:0.3-0.9:38.5-64.2; preferably, the molar ratio of Fe element, Zn element and Mg element is 1:0.3:38.
5.
4. The NA-Fe, Zn, Mg chelate according to claim 2, characterized in that: In the NA-Fe, the molar ratio of NA to Fe is 10:1-1:1; In the NA-Zn, the molar ratio of NA to Zn element is 10:1-1:1; In the NA-Mg, the molar ratio of NA to Mg element is 10:1-1:
1.
5. The method for preparing the NA-Fe, Zn, Mg chelate according to any one of claims 1 to 4, characterized in that: The following steps are involved: The ferrous compound reacts with NA in water to obtain NA-Fe; reacting a zinc compound with NA in water to obtain NA-Zn; reacting a magnesium compound with NA in water to obtain NA-Mg; NA-Fe, NA-Zn and NA-Mg are mixed to obtain the NA-Fe, Zn, Mg chelate.
6. The method for preparing the NA-Fe, Zn, Mg chelate according to claim 5, characterized in that: The ferrous compound includes ferrous chloride, ferrous sulfate, ferrous nitrate or ferrous lactate; The zinc compound includes zinc sulfate, zinc chloride, zinc nitrate or zinc acetate; The magnesium compound includes magnesium sulfate, magnesium chloride, magnesium nitrate or magnesium chromate; In the step of mixing NA-Fe, NA-Zn and NA-Mg, the ratio of the NA-Fe, the NA-Zn and the NA-Mg satisfies that the molar ratio of the Fe element, the Zn element and the Mg element is 1:0.3-0.9:38.5-64.
2.
7. The method for preparing the NA-Fe, Zn, Mg chelate according to claim 5, characterized in that: In the step of reacting the ferrous compound with NA in water to obtain NA-Fe, the ferrous compound is added to the water, NA is added within a preset time range, the temperature is controlled at the reaction temperature, the reaction is carried out for a preset reaction time, a colorless solution is generated, the solution is purified, and dried to obtain the NA-Fe; In the step of reacting the zinc compound with NA in water to obtain NA-Zn, the zinc compound is added to water, NA is added within a preset time range, the temperature is controlled at a reaction temperature, the reaction is carried out for a preset reaction time, a colorless solution is generated, the solution is purified, and dried to obtain the NA-Zn; In the step of reacting the magnesium compound with NA in water to obtain NA-Mg, the magnesium compound is added to the water, NA is added within a preset time range, the temperature is controlled at the reaction temperature, the reaction is carried out for a preset reaction time, a colorless solution is generated, the solution is purified, and dried to obtain the NA-Mg; Preferably, the preset time range is 5-20 minutes, the molar ratio of the NA to the ferrous compound, the zinc compound or the magnesium compound is 10:1-1:1, the reaction temperature is 25-37°C, the preset reaction time is 15min-24h, the reaction is carried out under vortex oscillation, the purification is performed by preparative chromatography on the sample, and the drying is performed by N2 drying.
8. The method for preparing the NA-Fe, Zn, Mg chelate according to claim 5 or 7, characterized in that: The step of reacting the ferrous compound with NA in water to obtain NA-Fe is carried out in the presence of a reducing agent, wherein the reducing agent includes ascorbic acid, sodium citrate, potassium tartrate or sodium phosphite. In the reaction system, the concentration of the reducing agent is 5-15 mmol / L.
9. Use of the NA-Fe, Zn, Mg chelate according to any one of claims 1 to 4 in the preparation of a medicament for treating and / or preventing ischemic anemia, and / or preventing and treating anemia caused by insufficient or impaired utilization of hematopoietic raw materials.
10. A pharmaceutical composition containing NA-Fe, Zn, Mg chelate, characterized in that: The pharmaceutical composition is a powder, granules, tablets, pills, capsules or syrup containing the NA-Fe, Zn, Mg chelate according to any one of claims 1 to 4; preferably, the pharmaceutical composition is a capsule containing the NA-Fe, Zn, Mg chelate; further preferably, the daily dose of the pharmaceutical composition is no more than 62 mg / kg body weight based on the NA-Fe, Zn, Mg chelate.
Citation Information
Cited By
Method for preparing high-bioavailability iron material by extracting acidic phospholipid from soybean oil processing waste liquid
CN121361914A
